New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
November 4, 2009
10:00 EDTMNTA
theflyonthewall.com: Momenta Pharmaceuticals March volatility elevated at 125 into FDA
Momenta Pharmaceuticals is recently up 1c to $9.29. The FDA is expected to make a decision on MNTA's M-Enoxaparin (treatment for deep vein thrombosis) in the next nine-months. MNTA November option implied volatility is at 69, January is at 103 and March is at 125; verses its 26-week average of 98 according to Track Data, suggesting larger price movement in 2010. :theflyonthewall.com



News For MNTA From The Last 14 Days
Check below for free stories on MNTA the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2012
09:54 EDTMNTA
theflyonthewall.com: Momenta Pharma gaps down after results, support is at $14.50, $14.25

Subscribe for More Information :theflyonthewall.com
09:48 EDTMNTA
theflyonthewall.com: Gappers report: Bearish gaps

Subscribe for More Information :theflyonthewall.com
08:34 EDTMNTA
theflyonthewall.com: Momenta Pharma reports Q4 EPS (2c) vs. consensus (27c)
Reports revenue $29.5M vs. consensus $38.59M. :theflyonthewall.com

February 7, 2012
13:45 EDTMNTA
theflyonthewall.com: Judge rules for FDA, against Sanofi, in generic Lovenox appeal, Bloomberg says

Subscribe for More Information :theflyonthewall.com